HETLIOZ
Total Payments
$3.5M
Transactions
84,949
Doctors
18,161
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $420,575 | 15,704 | 5,794 |
| 2023 | $607,263 | 16,389 | 5,770 |
| 2022 | $1.6M | 24,330 | 7,774 |
| 2021 | $662,507 | 19,941 | 6,743 |
| 2020 | $294,475 | 8,585 | 3,326 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.8M | 84,785 | 50.1% |
| Unspecified | $1.7M | 155 | 46.8% |
| Charitable Contribution | $60,000 | 3 | 1.7% |
| Consulting Fee | $52,184 | 3 | 1.5% |
| Education | $36.52 | 2 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30.83 | 1 | 0.0% |
Payments by Type
General
$1.9M
84,794 transactions
Research
$1.7M
155 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) | Vanda Pharmaceuticals Inc. | $757,327 | 1 |
| AN OPEN-LABEL, TWO-PERIOD, RANDOMIZED, SINGLE ORAL DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF 20 MG TASIMELTEON CAPSULE FORMULATION RELATIVE TO 5 ML TASIMELTEON LIQUID SUSPENSION FORMULATION IN HEALTHY VOLUNTEERS | Vanda Pharmaceuticals Inc. | $596,202 | 0 |
| EVALUATING THE EFFECTS OF TASIMELTEON VS PLACEBO ON SLEEP DISTURBANCES IN SMS | Vanda Pharmaceuticals Inc. | $231,664 | 1 |
| EVALUATING THE EFFECTS OF TASIMELTEON IN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER (ASD) AND SLEEP DISTURBANCES | Vanda Pharmaceuticals Inc. | $44,167 | 0 |
| A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TASIMELTEON IN TREATING SLEEP DISTURBANCES IN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER | Vanda Pharmaceuticals Inc. | $21,025 | 0 |
| EVALUATING THE EFFECTS OF TASIMELTEONIN INDIVIDUALS WITH AUTISM SPECTRUM DISORDER (ASD) AND SLEEP DISTURBANCES | Vanda Pharmaceuticals Inc. | $9,350 | 0 |
Top Doctors Receiving Payments for HETLIOZ
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $1.7M | 186 |
| , M.D | Contractor | San Francisco, CA | $23,806 | 4 |
| , MD | Psychiatry | Tampa, FL | $19,877 | 3 |
| , M.D | Psychiatry | Brandon, FL | $2,199 | 87 |
| , PMHNP-BC | Addiction (Substance Use Disorder) | Pasadena, CA | $1,880 | 75 |
| , PMHNP | Psychiatric/Mental Health | Palm Harbor, FL | $1,762 | 71 |
| , ARNP | Psychiatric/Mental Health | Brandon, FL | $1,683 | 61 |
| , PA-C | Medical | Costa Mesa, CA | $1,656 | 63 |
| , MD | Psychiatry | Hallandale Beach, FL | $1,586 | 80 |
| , PMHNP-BC | Psychiatric/Mental Health | Costa Mesa, CA | $1,554 | 61 |
| , DO | Psychiatry | Merrillville, IN | $1,508 | 52 |
| Troy Noonan | — | Brandon, FL | $1,468 | 67 |
| , M.D | Psychiatry | Rockford, IL | $1,451 | 63 |
| , M.D | Psychiatry | Greenbelt, MD | $1,442 | 70 |
| , M.D | Psychiatry | Miami, FL | $1,439 | 59 |
| , MD | Psychiatry | Milwaukee, WI | $1,437 | 58 |
| , M.D | Psychiatry | Costa Mesa, CA | $1,403 | 55 |
| , M.D | Psychiatry | Glendora, CA | $1,401 | 49 |
| , M.D | Psychiatry | Las Vegas, NV | $1,395 | 56 |
| Derek Ott | — | Los Angeles, CA | $1,389 | 53 |
| , MD | Family Medicine | East Chicago, IN | $1,371 | 48 |
| , MD | Psychiatry | Warren, MI | $1,359 | 67 |
| , M.D | Internal Medicine | Downey, CA | $1,350 | 60 |
| , M.D | Mental Health | Glendale, CA | $1,334 | 49 |
| , PMHNP-BC | Registered Nurse | Jacksonville, NC | $1,328 | 65 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 18,161
- Transactions 84,949
About HETLIOZ
HETLIOZ is a drug associated with $3.5M in payments to 18,161 healthcare providers, recorded across 84,949 transactions in the CMS Open Payments database. The primary manufacturer is Vanda Pharmaceuticals Inc..
Payment data is available from 2020 to 2024. In 2024, $420,575 was paid across 15,704 transactions to 5,794 doctors.
The most common payment nature for HETLIOZ is "Food and Beverage" ($1.8M, 50.1% of total).
HETLIOZ is associated with 6 research studies, including "EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD)" ($757,327).